310 results about "Immediate release" patented technology

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a meloabalin besylate double-release preparation and a preparation method thereof. Comprising a quick-release pellet and a sustained-release pellet, and the quick-release pellet and the sustained-release pellet are wrapped in a hollow capsule; the quick-release pellet comprises a quick-release blank pellet core, a quick-release drug layer and a quick-release film coating layer; the sustained-release pellet comprises a sustained-release blank pellet core, a sustained-release drug layer, a sustained-release layer and a sustained-release film coating layer. According to the invention, the stable blood concentration is obtained while the medicine effect takes effect quickly, the medicine taking frequency is reduced, convenience is brought to patients, and the compliance is improved. The invention also provides a preparation method thereof.

The invention discloses a nano-film for relieving bone fracture pain and a preparation method thereof, and relates to the technical field of medical films, the nano-film comprises an inner layer, a middle layer and an outer layer, the three layers are prepared by mixing traditional Chinese medicine extracts and base materials, the nano-film is prepared through an electrostatic spinning technology, the components of all the layers are the same, but the proportions are different, and the inner layer and the middle layer are different. Wherein a polycaprolactone and polyvinyl alcohol blending system is selected as the base material; the inner layer has high drug-loading capacity to quickly relieve symptoms, the middle layer has continuous release, the outer layer has low drug-loading capacity to reduce initial stimulation and increase stability, the use frequency is reduced, the drug effect is prolonged, and adverse reactions are reduced; the functions of protection, slow release and quick release are realized only by adjusting the proportion of PCL / PVA, and the production process is simplified.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The invention provides a medicine composition containing vinloxacin hydrochloride. The medicine composition comprises a quick-release pellet and a sustained-release pellet. The pharmaceutical composition provided by the invention has the advantages of good stability, capability of simultaneously meeting the specific requirement on in-vitro dissolution of the viloxin hydrochloride, small variety and dosage of auxiliary materials, higher safety and suitability for preparation of a preparation. And the protective layer is sprayed on the outer surface of the sustained-release layer, so that the advantages of weakening the electrostatic interaction of the pellets and preventing the particles from caking in the aging process are further achieved. In addition, the invention also provides a preparation method of the pharmaceutical composition, and the method has the advantages of high drug application rate, less fine powder, no filter bag and spray gun head blockage phenomenon, and suitableness for industrial production and application.

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).

The present invention relates to a bilayer tablet comprising extended-release formulation having metformin or a pharmaceutically acceptable salt thereof and at least one cellulose derivates as binder and immediate release formulation having sitagliptin or a pharmaceutically acceptable salt thereof and at least one antioxidant. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process of preparing the bilayer tablet.

The present invention discloses modified-release bilayer tablets consisting of two layers, layer 1 consisting 500 mg sustained release metformin and layer 2 consisting 250 mg normal release metformin and 5mg / 10mg delayed-release dapagliflozin. This formulation is meticulously designed to regulate blood glucose levels effectively over an extended period. Immediate-release metformin swiftly addresses acute glucose spikes, while sustained-release metformin ensures prolonged glucose control, minimizing fluctuations throughout the day. The delayed-release dapagliflozin component allows for controlled and timed release, managing persistent hyperglycemia synergistically with metformin. By optimizing efficacy and minimizing glucose fluctuations, this innovative formulation offers a promising solution for stable glycemic control in individuals with diabetes. Present invention aims to improve patient outcomes and enhance overall quality of life by maintaining stable glucose levels and reducing the risk of complications associated with uncontrolled diabetes.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a sustained-release oral soluble film and a preparation method thereof, and the sustained-release oral soluble film comprises a sustained-release pellet core, a film forming material, a plasticizer and a flavoring agent. According to the invention, a multi-unit drug delivery system is provided, a small-particle-size film-controlled sustained-release pellet core is firstly prepared as an intermediate and then added into a film-forming material to form the oral-soluble film preparation, so that the limitation that the oral-soluble film is only applied as a quick-release preparation generally is broken through; the invention provides a slow-release oral soluble film preparation which is convenient for accurately dividing dosage, has better taste, can improve the medicine taking convenience and compliance of patients and has stable and lasting blood concentration.

The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.

The invention provides a nicotine orally disintegrating tablet with a multi-layer composite sustained-release structure and a preparation method of the nicotine orally disintegrating tablet. The nicotine orally disintegrating tablet comprises an inner layer, a middle layer and an outer layer, wherein the middle layer and the outer layer sequentially coat the inner layer from inside to outside; the outer layer comprises nicotine, instant starch and a lubricant; the middle layer comprises nicotine, ethyl cellulose, polyethylene glycol and a flow aid; the inner layer comprises the following components: nicotine nanoparticles coated with chitosan and sodium tripolyphosphate, an oral microenvironment regulator and a filling agent. According to the nicotine orally disintegrating tablet provided by the invention, due to the gradient coating structure design of the inner layer, the middle layer and the outer layer, the multi-stage accurate release of nicotine, namely early-stage quick release, middle-stage stable release and later-stage slow release, is realized, the reactions of dizziness, vomiting and the like caused by excessive release of nicotine are avoided, and the use comfort is improved. Meanwhile, the pH value of the oral cavity is adjusted, micro-ecological balance of the oral cavity is maintained, the content of volatile sulfide in breath is reduced, and breath is refreshed.

The invention discloses a gastric retention double-layer sustained-release tablet and a preparation method and application thereof, and belongs to the field of pharmaceutical preparations, the active ingredient of the gastric retention double-layer sustained-release tablet is 3-[4-[4-(lH-benzotriazole-1-yl) butyl] piperazine-1-yl] benzisothiazole hydrochloride, and the gastric retention double-layer sustained-release tablet is composed of a quick-release drug release layer and a sustained-release drug release layer, the quick release layer contains an active component, a filler I and a disintegrating agent; and the sustained-release layer contains an active component, a filler II, an expansion material, a release retardant, an expansion accelerator and a stabilizer. According to the gastro-retention double-layer sustained-release tablet, the quick-release layer can quickly release the medicine to reach the effective blood concentration, and the retention time of the tablet in the stomach is prolonged after the sustained-release layer expands, so that the in-vivo absorption window of the medicine is prolonged, the maintenance of the blood concentration is realized, the in-vivo half-life period of active ingredients is remarkably prolonged, the administration frequency can be reduced, and the compliance of a patient is improved. The product is simple in preparation process, suitable for industrial production and wide in development prospect.

Disclosed are an ibuprofen pharmaceutical composition, and a preparation method therefor and the use thereof. The ibuprofen pharmaceutical composition comprises the following components: sustained-release pellets and immediate-release pellets, wherein the sustained-release pellets comprise ibuprofen, a filler and an adhesive; and the immediate-release pellets comprise ibuprofen, a filler, a suspending agent, a disintegrant, a flavoring agent and a pH regulator. The ibuprofen pharmaceutical composition takes effect quickly and can maintain a therapeutic effect for a long time. The administration compliance of children, elderly people and people with dysphagia can be effectively improved, and the administration frequency is reduced. A dry deposition particle has a wide loading range, and the presence of the dry deposition particle during drug storage and transportation is beneficial for maintaining the stability during drug storage and transportation. In addition, the ibuprofen pharmaceutical composition has the advantages of a simple preparation process, stable properties and convenient administration, and is suitable for industrial production.

The invention provides a novel analgesic injection composition. The composition comprises tapentadol in an active ingredient quick release form and a quick-acting and long-acting composition of bistapentadol sebacate in an active ingredient slow release form. The invention also relates to a method for preparing the quick-acting and long-acting injection composition and application of the prepared dosage form in preparation of medicines for treating chronic or acute pain, such as preoperative and postoperative administration. The quick-acting and long-acting injection composition provided by the invention has ideal pharmaceutical technology and clinical attributes.

The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains a decarboxylase inhibitor wherein the one or more controlled release components are substantially free of the decarboxylase inhibitor.

Compositions for the immediate release of one or more cannabinoids, in which the compositions comprise a population of particles. Each particle may comprise the one or more cannabinoids and one or more intra-granule excipients. Alternatively, each particle may comprise the one or more cannabinoids and a porous bead core. The composition may be prepared by a method that involves combining the one or more cannabinoids with the one or more intra-granule excipients, and then granulating the combination, such as through fluid bed granulation, shear-induced wet granulation, or spray granulation. The composition may also be prepared by a method that involves mixing the one or more cannabinoids with a population of porous bead cores.

The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains carbidopa and about 80% to 100% of the carbidopa in the oral solid formulation is present in the one or more immediate release components.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.

The present invention provides a solid, immediate- and rapid-release pharmaceutical composition with improved stability, comprising enalapril maleate and pharmaceutically acceptable excipients. Also described are the use thereof and a method for preparing the solid, immediate- and rapid-release pharmaceutical composition with improved stability, comprising enalapril maleate and pharmaceutically acceptable excipients.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention provides a quick-release composition, the quick-release composition contains sacubitril valsartan or a salt thereof and amlodipine or a salt thereof, and the two active components in the quick-release composition can realize quick release. The invention also relates to application of sacubitril valsartan or salt thereof, amlodipine or salt thereof and a quick-release composition thereof in preparation of medicaments for treating cardiovascular diseases.

The invention provides a loxoprofen sodium double-release capsule micro-tablet and a preparation method of the loxoprofen sodium double-release capsule micro-tablet. Through the synergistic effect of the quick-release micro-tablet and the sustained-release micro-tablet, the quick-release micro-tablet can realize quick release and absorption, and the sustained-release micro-tablet can maintain relatively stable blood concentration for a long time. The administration frequency is reduced, the coordination of the postprandial administration requirement and the dietary habit is ensured, and the occurrence of gastrointestinal tract adverse reactions is reduced. The preparation provided by the invention conforms to the dosage form design of the hour pharmacology, can quickly take effect through administration twice every day, can maintain the blood concentration in the high-incidence time period of night diseases, avoids the disadvantage of taking medicine after meal when the night diseases attack, guarantees the sleep quality, and improves the overall treatment effect. The micro tablet is small in size and easy to swallow, and the medication compliance of patients with dysphagia is obviously improved. Through dosage form design and improvement, unmet clinical requirements are expected to be met by virtue of obvious advantages of the traditional Chinese medicine composition.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention relates to the technical field of burn and scald treatment, in particular to an intelligent hydrogel dressing for targeted regulation and control of Mongolian medicine release. The dressing comprises a core-shell microsphere drug loading system used for realizing physical segmentation of a functional area; the dual-release system is used for realizing surface adsorption of quick-release drug nanoparticles and internal wrapping of sustained-release microspheres; a hydrogel matrix for forming a nanofiber network; and the magnetic control regulator is magnetic nanoparticles dispersed in the hydrogel matrix, and regulates the aperture of the hydrogel network through the action of an external magnetic field. According to the intelligent hydrogel dressing for targeted regulation and control of Mongolian medicine release, the Mongolian medicine compound intelligent hydrogel dressing is developed on the basis of a TRIZ innovative method; through a core-shell microsphere drug loading system and a dual release design, high drug loading capacity and accurate drug release control are synchronously realized.

The invention is a method for treating patients with Parkinson's disease, primary parkinsonism / idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The present invention relates to a tablet formulation comprising a core tablet having metformin and at least one matrix agent and a coating solution having sitagliptin surrounding the core tablet and a film coating wherein the coating solution further comprises at least one antioxidant and at least one coating agent. Further, the present invention provides a method for the preparation of said composition.